Tuesday, July 1, 2025

Biogen Pays $900 Million To Settle Kickback Lawsuit

Biogen, Inc (NASDAQ: BIIB) has reached a US$900 million deal to resolve a long-running whistleblower lawsuit concerning its multiple sclerosis drugs, the company said in its quarterly earnings report on Wednesday.

The lawsuit, which was filed in 2015 by a former employee, alleges that the Massachusettes-based biotechnology company paid kickbacks to doctors to amp up prescriptions of Tecfidera, Tysabri and Avonex, the company’s drugs for multiple sclerosis.

The agreement-in-principle came just days before the trial was set to begin on Tuesday in a Boston federal court. The amount that the company paid is just a little short of the US$981.1 million that the plaintiff, Michael Bawduniak, was seeking in damages.

Bawduniak was a sales rep at the company from 2004 to 2012. He alleged that Biogen used consulting meetings and speaking events as cover to offer kickbacks to physicians. When he tried to stop the payment of these alleged kickbacks in 2011, he was demoted from a director of regional marketing position.

According to Biogen, the settlement doesn’t include any admission of liability. The two parties have yet to finalize the agreement.

This settlement comes at a difficult period for Biogen and its multiple sclerosis franchise. The franchise faces continuous sales declines from the emergence of generics and newer competition.

Biogen last traded at US$214.06 on the Nasdaq.


Information for this briefing was found via Biogen, Reuters and the sources mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Biogen Trades At 12-Month High Following Alzheimer’s Drug Success, US$900-Million Settlement On Kickback Lawsuit

Fresh off a US$900 million settlement agreement, Biogen, Inc (Nasdaq: BIIB) announced positive topline results...

Wednesday, September 28, 2022, 03:04:00 PM

Biogen Wins Approval with FDA for Alzheimer’s Drug

This morning Biogen (NASDAQ:BIIB) received approval from the FDA for their Alzheimer’s drug aducanumab. The...

Monday, June 7, 2021, 11:49:16 AM

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc (NASDAQ: BIIB) appears to be facing issues related to its executive team. The...

Monday, January 31, 2022, 08:38:57 AM

Samsung In Talks To Acquire Biotech Firm Biogen In A US$42 Billion Deal

The Samsung Group is reportedly in negotiations to acquire biotech firm Biogen (Nasdaq: BIIB). The...

Thursday, December 30, 2021, 11:40:00 AM